Trial · NCT03222609
Adverse events1,012
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 1,012
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | SPLENOMEGALY | Blood and lymphatic system disorders | Navitoclax + Ruxolitinib (Cohort 1a) | 2 | 34 | 2 |
| other | SPLENOMEGALY | Blood and lymphatic system disorders | Navitoclax + Ruxolitinib (Cohort 1b) | 1 | 91 | 1 |
| other | SPLENOMEGALY | Blood and lymphatic system disorders | Navitoclax (Cohort 2) | 0 | 34 | 0 |
| other | SPLENOMEGALY | Blood and lymphatic system disorders | Navitoclax + Ruxolitinib (Cohort 3) | 0 | 32 | 0 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Navitoclax + Ruxolitinib (Cohort 1a) | 30 | 34 | 134 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Navitoclax + Ruxolitinib (Cohort 1b) | 45 | 91 | 146 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Navitoclax (Cohort 2) | 10 | 34 | 28 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Navitoclax + Ruxolitinib (Cohort 3) | 18 | 32 | 75 |
| other | EAR PAIN | Ear and labyrinth disorders | Navitoclax + Ruxolitinib (Cohort 1a) | 2 | 34 | 2 |
| other | EAR PAIN | Ear and labyrinth disorders | Navitoclax + Ruxolitinib (Cohort 1b) | 0 | 91 | 0 |
| other | EAR PAIN | Ear and labyrinth disorders | Navitoclax (Cohort 2) | 1 | 34 | 1 |
| other | EAR PAIN | Ear and labyrinth disorders | Navitoclax + Ruxolitinib (Cohort 3) | 0 | 32 | 0 |
| other | TINNITUS | Ear and labyrinth disorders | Navitoclax + Ruxolitinib (Cohort 1a) | 2 | 34 | 2 |
| other | TINNITUS | Ear and labyrinth disorders | Navitoclax + Ruxolitinib (Cohort 1b) | 1 | 91 | 1 |
| other | TINNITUS | Ear and labyrinth disorders | Navitoclax (Cohort 2) | 0 | 34 | 0 |
| other | TINNITUS | Ear and labyrinth disorders | Navitoclax + Ruxolitinib (Cohort 3) | 3 | 32 | 3 |
| other | VERTIGO | Ear and labyrinth disorders | Navitoclax + Ruxolitinib (Cohort 1a) | 0 | 34 | 0 |
| other | VERTIGO | Ear and labyrinth disorders | Navitoclax + Ruxolitinib (Cohort 1b) | 2 | 91 | 2 |
| other | VERTIGO | Ear and labyrinth disorders | Navitoclax (Cohort 2) | 0 | 34 | 0 |
| other | VERTIGO | Ear and labyrinth disorders | Navitoclax + Ruxolitinib (Cohort 3) | 2 | 32 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03222609/events?page=2